Travere Therapeutics, Inc. (TVTX) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
TVTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TVTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.9% | -12.8% | -5.2% |
| 2024 | 96.7% | -138.9% | -137.9% |
| 2023 | 92.1% | -267.2% | -76.7% |
| 2022 | 96.0% | -292.2% | -254.4% |
| 2021 | 97.1% | -151.3% | -136.6% |
Download Data
Export TVTX earnings history in CSV or JSON format
Free sign-in required to download data
Travere Therapeutics, Inc. (TVTX) Earnings Overview
As of May 8, 2026, Travere Therapeutics, Inc. (TVTX) reported trailing twelve-month net income of -$21M, reflecting +86.3% year-over-year growth. The company earned $-0.23 per diluted share over the past four quarters, with a net profit margin of -5.2%.
Looking at the long-term picture, TVTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $117M in fiscal 2015.
Travere Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), TVTX has outperformed on profitability metrics. Compare TVTX vs RARE →
TVTX Earnings vs Peers
Earnings metrics vs comparable public companies
TVTX Historical Earnings Data (2008–2025)
16 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | +92.1% | -$63M | $-0.56 | -5.2% | -12.8% |
| 2024 | -$322M | -188.6% | -$324M | $-4.08 | -137.9% | -138.9% |
| 2023 | -$111M | +60.0% | -$388M | $-1.50 | -76.7% | -267.2% |
| 2022 | -$278M | -54.6% | -$320M | $-4.37 | -254.4% | -292.2% |
| 2021 | -$180M | -6.3% | -$199M | $-3.01 | -136.6% | -151.3% |
| 2020 | -$169M | -15.7% | -$176M | $-3.56 | -85.4% | -88.8% |
| 2019 | -$146M | -42.6% | -$100M | $-3.46 | -83.5% | -56.9% |
| 2018 | -$103M | -71.9% | -$80M | $-2.54 | -62.5% | -48.7% |
| 2017 | -$60M | -24.7% | -$54M | $-1.54 | -38.6% | -34.7% |
| 2016 | -$48M | -140.9% | -$58M | $-1.25 | -35.9% | -43.6% |
See TVTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TVTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TVTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTVTX — Frequently Asked Questions
Quick answers to the most common questions about buying TVTX stock.
Is TVTX growing earnings?
TVTX EPS is $-0.23, with earnings growth accelerating to +86.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-21M.
What are TVTX's profit margins?
Travere Therapeutics, Inc. net margin is -5.2%, with operating margin at -12.8%. Below-average margins reflect competitive or cost pressures.
How consistent are TVTX's earnings?
TVTX earnings data spans 2008-2025. The accelerating earnings trend is +86.3% YoY. Historical data enables comparison across business cycles.